Research Grade Anti-Human FGF19 (1A6)

Catalog No.

DHB73301

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG

Clonality

Monoclonal

Target

FGF19, Fibroblast growth factor 19, FGF-19

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O95750

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

U3-1784

Clone ID

U3-1784

Lenvatinib suppress FGF19-FGFR4 signaling to enhance antitumor immune response in gastric cancer., PMID:39948303

Targeted proteomics of cerebrospinal fluid in treatment naïve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes., PMID:39294186

Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab., PMID:39197925

The Immune Signature of CSF in Multiple Sclerosis with and without Oligoclonal Bands: A Machine Learning Approach to Proximity Extension Assay Analysis., PMID:38203309

Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7., PMID:38154497

FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1., PMID:38048735

FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2., PMID:36907560

A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma., PMID:36763233

Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients., PMID:36622048

Fibroblast Growth Factor-Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications., PMID:36100222

The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody., PMID:35874743

Combined inhibition of FGFR4 and VEGFR signaling enhances efficacy in FGF19 driven hepatocellular carcinoma., PMID:35812049

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors., PMID:35655320

Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19., PMID:35479098

EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma., PMID:35371031

A Potential Role for Bile Acid Signaling in Celiac Disease-Associated Fatty Liver., PMID:35208205

Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma., PMID:33794926

S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways., PMID:33389337

FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with α-Klotho., PMID:33257569

Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma., PMID:33182650

Upregulation of circulating inflammatory biomarkers under the influence of periodontal disease in rheumatoid arthritis patients., PMID:32403006

Current and new pharmacotherapy options for non-alcoholic steatohepatitis., PMID:32237916

Novel Abs targeting the N-terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile-acid-related side-effects., PMID:32061104

Hypoxia Rapidly Induces the Expression of Cardiomyogenic Factors in Human Adipose-Derived Adherent Stromal Cells., PMID:31443313

Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity., PMID:31350344

Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis., PMID:30679232

Work in Progress: Drugs in Development., PMID:30259849

NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial., PMID:30202819

Therapeutics Highlights from ILC 2018, the EASL annual congress., PMID:30143450

FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia., PMID:28988823

Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD., PMID:28746779

Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis., PMID:28508871

Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome., PMID:28275113

FGF19 functions as autocrine growth factor for hepatoblastoma., PMID:27382436

FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)., PMID:27245147

Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival., PMID:27192118

Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders., PMID:26594197

Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex., PMID:26288846

New molecular therapies for hepatocellular carcinoma., PMID:26206572

Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy., PMID:24662279

Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer., PMID:23536011

Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models., PMID:22615798

Understanding the structure-function relationship between FGF19 and its mitogenic and metabolic activities., PMID:22396171

Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys., PMID:22268002

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening., PMID:21397858

Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma., PMID:21109934

The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells., PMID:19946327

Subtype-specific expression of Fgf19 during horizontal cell development of the chicken retina., PMID:19272464

Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation., PMID:19240166

Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression., PMID:19085950

Document Download

Research Grade Anti-Human FGF19 (1A6).pdf